Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-optiE7
- Development stage
- Unknown
- Lead developer
- Pasteur Institute of Iran
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-optiE7 is a genetically engineered, live bacterial therapeutic vaccine designed for the prevention and treatment of human papillomavirus type 16 (HPV-16) related diseases, such as cervical cancer and premalignant lesions. The vaccine utilizes the *Lactococcus lactis* strain NZ9000 as a delivery vector to express a codon-optimized version of the full-length HPV-16 E7 oncoprotein. Administered orally, the vaccine aims to induce a mucosal and systemic immune response against E7-expressing cells. Clinical evaluation in Iran has demonstrated that the vaccine is well-tolerated in healthy volunteers, with the potential to serve as a cost-effective and non-invasive immunotherapy for HPV-associated malignancies.
- Other names
- recombinant L. lactis NZ9000 pNZ8123-HPV16-optiE7Lactococcus lactis NZ9000 pNZ8123-HPV16-optiE7
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-optiE7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant Lactococcus lactis NZ9000 pNZ8123-HPV16-optiE7.